Systems-level biomarkers identification and drug repositioning in colorectal cancer.

Abstract

Colorectal cancer (CRC) is the most commonly diagnosed fatal cancer in both women and men worldwide. CRC ranked second in mortality and third in incidence in 2020. It is difficult to diagnose CRC at an early stage as there are no clinical symptoms. Despite advances in molecular biology, only a limited number of biomarkers have been translated into routine clinical practice to predict risk, prognosis and response to treatment. In the last decades, systems biology approaches at the omics level have gained importance. Over the years, several biomarkers for CRC have been discovered in terms of disease diagnosis and prognosis. On the other hand, a few drugs are being developed and used in clinics for the treatment of CRC. However, the development of new drugs is very costly and time-consuming as the research and development takes about 10 years and more than $1 billion. Therefore, drug repositioning (DR) could save time and money by establishing new indications for existing drugs. In this review, we aim to provide an overview of biomarkers for the diagnosis and prognosis of CRC from the systems biology perspective and insights into DR approaches for the prevention or treatment of CRC.

• Authors: Hande Beklen, Esra Yildirim, Medi Kori, Beste Turanli, Kazim Yalcin Arga
• Journal: World journal of gastrointestinal oncology (World J Gastrointest Oncol) Vol. 13 Issue 7 Pg. 638-661 (Jul 15 2021) ISSN: 1948-5204 [Print] China
• PMID: 34322194 (Publication Type: Journal Article, Review)
• Copyright: ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.